Australia's Cleo Diagnostics rises to near 2-month high on US approval for trial

CLEO Diagnostics

25/06/2025 04:42

** Shares of Cleo Diagnostics COV.AX rise as much as 17.7% to A$0.400, their highest level since May 5

** Stock set for its best day since April 14, if trends sustain

** The cancer diagnostics tests provider receives approval from U.S. National Cancer Institute to access blood samples from the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial

** Around 209,750 shares change hands, busiest day since May 19

** Stock up 4.2%, YTD

 (Reporting by Keshav Singh Chundawat in Bengaluru)

 ((Keshav.SinghChundawat@thomsonreuters.com))